RT Journal Article
T1 Impact of Canagliflozin in Patients with Type 2 Diabetes after Hospitalization for Acute Heart Failure: A Cohort Study
A1 Martín, Ernesto
A1 López-Aguilera, José
A1 González-Manzanares, Rafael
A1 Anguita, Manuel
A1 Gutiérrez, Guillermo
A1 Luque, Aurora
A1 Paredes, Nick
A1 Oneto, Jesús
A1 Perea, Jorge
A1 Castillo, Juan Carlos
K1 Heart failure
K1 Readmissions
K1 Canagliflozin
K1 Sodium glucose co-transporter 2 inhibitor
K1 N-terminal pro-B-type natriuretic peptide
K1 Type 2 diabetes mellitus
K1 Insuficiencia cardíaca
K1 Readmisión del paciente
K1 Canagliflozina
K1 Inhibidores del cotransportador de sodio-glucosa 2
K1 Péptidos natriuréticos
K1 Diabetes mellitus tipo 2
AB Background: Heart failure (HF) is one of the mayor contributors to cardiovascular morbidity and mortality in patients with diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have demonstrated to reduce the risk of hospitalization for HF in patients with type 2 diabetes mellitus (T2D). We aimed to assess the risk for re-hospitalization in a cohort of patients hospitalized for HF according to whether or not they received canagliflozin at discharge, as well as changes in N-terminal pro–B-type natriuretic peptide (NT-ProBNP) concentration during follow-up. Methods: We conducted a retrospective longitudinal study at a tertiary centre including 102 consecutive T2D patients discharged for acute HF without contraindication for SGLT2 inhibitors. We compared adverse clinical events (HF rehospitalization and cardiovascular death) and NT-ProBNP changes according to canagliflozin prescription at discharge. Results: Among the 102 patients included, 45 patients (44.1%) were prescribed canagliflozin and the remaining 57 (55.9%) were not prescribed any SGLT2 inhibitors (control group). After a median follow-up of 22 months, 45 patients (44.1%) were hospitalized for HF. Most of the rehospitalizations occurred during the first year (37.3%). HF readmission at first year occurred in 10 patients (22.2%) in the canagliflozin group and 29 patients (49.1%) in the control group (hazard ratio (HR): 0.45; 95% confidence interval (CI): 0.21–0.96; p < 0.039). A composite outcome of hospitalization for HF or death from cardiovascular causes was lower in the canagliflozin group (37.8%) than in the control group (70.2%) (HR: 0.51; 95% CI: 0.27–0.95; p < 0.035). Analysis of NT-ProBNP concentration showed an interaction between canagliflozin therapy and follow-up time (p = 0.002). Conclusions: Canagliflozin therapy at discharge was associated with a lower risk of readmission for HF and a reduction in NT-ProBNP concentration in patients with diabetes after hospitalization for HF.
PB MDPI
YR 2021
FD 2021-02-01
LK http://hdl.handle.net/10668/4137
UL http://hdl.handle.net/10668/4137
LA en
NO Martín E, López-Aguilera J, González-Manzanares R, Anguita M, Gutiérrez G, Luque A, et al. Impact of Canagliflozin in Patients with Type 2 Diabetes after Hospitalization for Acute Heart Failure: A Cohort Study. J Clin Med. 2021 Feb 1;10(3):505.
DS RISalud
RD Apr 11, 2025